Discover trends, market shifts, and competitive outlooks for the keytruda industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has The Keytruda Market Size Shifted, And What Is the Outlook Through 2034?
The size of the Keytruda market has witnessed a rapid surge in recent times. It is projected to expand from a size of $21.6 billion in 2024 to reach $23.8 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.2%. Factors driving this growth during the historic phase include enhanced patient results, rising acceptance of immunotherapy, ongoing research and development, better patient adherence, and the higher incorporation of Keytruda.
The market size of Keytruda is forecasted to experience significant expansion in the approaching years, with an estimated value of $34.61 billion by 2029 at a compound annual growth rate (CAGR) of 9.8%. This projected growth during the forecast period can be linked to factors such as increasing indications, the emergence of new markets, growing cancer prevalence, escalating healthcare costs, and an increasing need for precision medicine. Notable trends anticipated during the forecast period involve the demand for targeted therapies, advancements in immunotherapy and diagnostic technologies, the need for cancer treatment, and progress in cancer research.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16457&type=smp
What Are the Core Market Drivers Propelling Growth in the Keytruda Industry?
The escalating incidences of cancer are predicted to drive the expansion of the keytruda market. Cancer is a diverse set of diseases marked by the erratic and rapid proliferation and propagation of cells. The surging numbers of cancer patients can be attributed to genetic, lifestyle, environmental, and hormonal influences. Keytruda, also known as pembrolizumab, aids in cancer treatment primarily by leveraging the body’s natural immunity to combat cancer cells more effectively. It marks a significant breakthrough in cancer therapy, utilizing the body’s immune system to target and eliminate cancer cells, thereby introducing novel prospects of recovery for many patients suffering from advanced or metastatic cancers. To illustrate, the American Cancer Society, an American non-profit cancer advocacy group, reported in January 2024 that the incidence of cancer rose to 2,001,140 from 1,958,310 in 2023, showing a growth of 2.19%. Hence, the burgeoning incidence of cancer fuels the growth of the keytruda market.
What Segment Types Define the Keytruda Market Structure?
The keytruda market covered in this report is segmented –
1) By Cancer Type: Melanoma, Lung Cancer, Head And Neck Cancer, Hodgkin Lymphoma, Stomach Cancer, Urothelial Carcinoma
2) By Payer Type: Commercial, Medicare, Medicaid
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Melanoma: Advanced Or Unresectable Melanoma, Adjuvant Treatment For Melanoma
2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Recurrent Or Metastatic Head And Neck Cancer
4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma
5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer, Esophagogastric Junction Cancer
6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Cancer
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16457&type=smp
Which Regions Are Driving the Next Phase of the Keytruda Market Growth?
North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing the Keytruda Industry Evolution?
Leading firms involved in the keytruda market are pioneering novel products like pembrolizumab to broaden the range of feasible treatments. Pembrolizumab is a type of monoclonal antibody medication, classified under immune checkpoint inhibitors and retailed under the brand, Keytruda. The drug targets and inhibits a protein known as PD-1 (programmed cell death protein 1), which is found on T immune cells. As an example, in November 2023, Merck, a US firm renowned for manufacturing keytruda, launched Keytruda (pembrolizumab) used alongside fluoropyrimidine- and platinum-containing chemotherapy approved by Food and Drug Administration, a US government agency. This combination showed notable advancements in general survival and halting disease progression as opposed to solo chemotherapy, showing promise in treating gastric cancer. Clinical trials have shown that this combined treatment increases general survival (OS), halts disease progression (PFS), and heightens overall response rate (ORR) compared to when chemotherapy is applied in isolation.
View the full report here:
https://www.thebusinessresearchcompany.com/report/keytruda-global-market-report
What Is the Definition of the Keytruda Market?
Keytruda is a brand name for pembrolizumab, a monoclonal antibody medication used in cancer treatment. Keytruda belongs to a class of drugs known as immune checkpoint inhibitors. It works by targeting and blocking a protein called PD-1 (programmed cell death protein 1) in immune cells, which helps the immune system recognize and attack cancer cells.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16457
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
